BIVI:NSD-BioVie Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.66

Change

-0.14 (-3.56)%

Market Cap

USD 0.10B

Volume

0.09M

Avg Analyst Target

USD 22.50 (+514.75%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

BioVie Inc (BIVI) Stock Analysis:
Based on the BioVie Inc stock forecasts from 1 analysts, the average analyst target price for BioVie Inc is USD 22.50 over the next 12 months. BioVie Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BioVie Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, BioVie Inc’s stock price was USD 3.66. BioVie Inc’s stock price has changed by -0.90% over the past week, -1.35% over the past month and -90.24% over the last year.

About

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic ...Read More

Company Website : https://www.biovieinc.com

Address : 2120 Colorado Avenue, Santa Monica, CA, United States, 90404

Employees : 6

Fiscal Year End : June

Currency: USD

Country : USA

Technical Indicators

Beta : 1.99

52 Week High : 46.10

Short Ratio : 4.92

52 Week Low : 3.70

Shorted Shares : 241,086

200 Day Moving Average : 10.07

Shorted Shares Previous Month : 256,075

50 Day Moving Average : 5.29

Shares Held By Insiders : 79.73%

Short Percentage : 5.02%

Shares Held by Institutions : 6.19%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.76 (-3.03%)

 USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

-18.29 (-2.94%)

 USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-2.57 (-1.12%)

 USD57.63B 27.19 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

+5.51 (+3.65%)

 USD36.62B 4.77 5.67
BGNE BeiGene Ltd

-15.38 (-6.18%)

 USD25.75B N/A N/A
SGEN Seagen Inc

-4.45 (-3.43%)

 USD23.69B 55.02 44.86
GMAB Genmab A/S

-1.55 (-4.54%)

 USD22.21B 50.69 6.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
RPRX Royalty Pharma plc

-0.34 (-0.86%)

 USD16.38B 19.81 11.89

ETFs Containing BIVI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.67% 52% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.67% 52% F 28% F
Trailing 12 Months  
Capital Gain -90.24% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.24% 2% F 2% F
Trailing 5 Years  
Capital Gain 2,184.64% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,184.64% 97% A+ 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 3,261.20% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3,261.20% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 6,730.98% 1% F 1% F
Risk Adjusted Return 48.45% 79% C+ 68% D+
Market Capitalization 0.10B 33% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.51 17% F 19% F
Price / Cash Flow Ratio -9.53 68% D+ 76% C
EV/EBITDA 16.21 22% F 43% F
Management Effectiveness  
Return on Equity -821.84% 3% F 2% F
Return on Invested Capital 1,777.07% 100% A+ 100% A+
Return on Assets -485.94% 0% N/A 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.92 35% F 22% F
Short Percent 5.02% 43% F 32% F
Beta 1.99 15% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector